Imprimis Pharmaceuticals has signed licensing agreement from resolutionMD, to provide resolutionMD with exclusive rights to the Accudel transdermal delivery technology, for anti cellulite formulations, in the global professional skincare market. As part of the agreement, resolutionMD will pay Imprimis a licensing royalty on the US and international sales. resolutionMD announced the new exclusive rights will help it to promote and sell cosmeceutical products in the global professional skincare market in consideration of certain royalties.

Imprimis Pharmaceuticals, Inc. announced that on February 18, 2013, Imprimis Pharmaceuticals, Inc. entered into a strategic alliance agreement with Professional Compounding Centers of America, Inc. Under the agreement, PCCA has agreed that during the term of the agreement, it will not introduce any of PCCA’s members or customers meeting certain criteria to any third party whereby such third party licenses or otherwise acquires the intellectual property rights of such Member/Customer, without first presenting such an opportunity to the company. PCCA may, but is not required to, present such opportunities to the company, use reasonable efforts to facilitate an introductory meeting between the Member/Customer and the company, and to further provide certain key technical assistance to a potential development project associated with the member/customer’s intellectual property rights. In the event the company and a member/customer introduced to the company by PCCA enter into a commercial agreement for the license or acquisition of the intellectual property rights owned by the Member/Customer, PCCA will be entitled to receive certain cash fees up to an aggregate of $100,000, as well as a commission based on net sales, if any, generated by the company as a result of the acquired intellectual property rights. The agreement has a term of one year and is automatically extended for successive one year periods unless either party gives the other written notice of non-renewal.

Imprimis Pharmaceuticals, Inc. announced the completion of a clinical study of Impracor(TM), a topical analgesic cream that delivers a therapeutic dose of the pain-relieving, anti-inflammatory drug ketoprofen. The study measured the amount of ketoprofen found in the bloodstream following topical application of two different doses of the anti-inflammatory cream under different conditions, including normal activities, heat exposure to the application site and exercising on a treadmill. In addition, the amount of the drug in the bloodstream after taking an oral dose of ketoprofen was studied in 40 healthy volunteers assigned to one of two cohorts (2g or 4g applications). Subjects were dosed according to a four-sequence, four-treatment randomization schedule in which they received topical Impracor applications under each of the three conditions and an oral ketoprofen dose in weekly intervals. Overall the pharmacokinetic parameters were very consistent between the two different dose cohorts. The application of an occlusive knee bandage with either heat or exercise following topical administration showed faster initial but lower overall plasma exposure of ketoprofen relative to non-occluded topical administration with no heat or exercise. The extent of bioavailability over 48 hours as measured by the Area under the concentration curve from time zero to the time of last measurable concentration (AUC0-t) was 2% or less in Cohort 1 (2 g single dose applied to one knee) and 4% or less in Cohort 2 (2 g single dose applied to each knee) for the topical treatments relative to the oral treatment.